Finally, only one study evaluated IL-1α expression using an in vitro model where breast cancer cells were treated with an endothelin-1 (ET-1) receptor dual antagonist, showing a local increase in breast cancer cell secretions of IL-1α [47]. Here, EDN1 is linked to breast cancer.